About Boundless Bio
Boundless Bio is a publicly listed company based in San Diego (United States) founded in 2018. Therapeutics for cancer are developed by targeting ecDNA. Boundless Bio has raised $251.99 million across 4 funding rounds from investors including Fidelity Investments, Bayer and ARE. The company has 64 employees. Boundless Bio offers products and services including ecDTx Therapies. Its focus areas include Life Sciences, Oncology, Drugs and Pan Cancer. Its legal entity is BOUNDLESS BIO, INC. Its competitors include TScan Therapeutics, Lyell Immunopharma and GigaGen; 3 of its 3 listed competitors have raised funding.
Company details
Boundless Bio was founded in 2018 and is headquartered in San Diego, United States. Operations center on the biotechnology sector, where therapeutics are developed to address cancer through targeting extrachromosomal DNA (ecDNA). Emphasis is placed on ecDNA biology to create treatments for patients with oncogene-amplified cancers that are difficult to manage. The companys domain is boundlessbio.com.
- Headquarters San Diego, United States
- Employees 64
- Stage Public
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website boundlessbio.com
- Social LinkedIn X
- Legal Name Boundless Bio, Inc.
- Net Profit-$58.2 M (USD)10.96as on Dec 31, 2025
- EBITDA-$62.3 M (USD)13.69as on Dec 31, 2025
- Total Equity Funding$251.99M (USD)
in 4 rounds
- Latest Funding Round$100M (USD), Series C
May 2023
- InvestorsFidelity Investments
& 20 more
- Employee Count64
Products & Services of Boundless Bio
Boundless Bio offers a comprehensive portfolio of products and services, including ecDTx Therapies.
Therapies targeting extrachromosomal DNA in oncogene amplified cancers
Funding Insights of Boundless Bio
Boundless Bio has successfully raised a total of $251.99M across 4 strategic funding rounds. The most recent funding activity was a Series C round of $100 million completed in May 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $251.99M
- Total Rounds 4
- Last Round Series C — $100M
- First Round $46.4M
(Sep 2019)
- Investors Count 21
All 4 funding rounds of Boundless Bio with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| May 2023 | $100M | Series C | – | Bayer, RA Capital Management | |
| Jun 2022 | $25M | Grant | – | – | |
| Apr 2021 | $105.59M | Series B | – | Nextech Invest, RA Capital Management | |
| Sep 2019 | $46.4M | Series A | – | City Hill Ventures, Arch Venture Partners |
21 investors in total: 21 institutional.
Investors in Boundless Bio
Boundless Bio has secured backing from 21 investors, including institutional and venture fund investors. Prominent investors backing the company include Fidelity Investments, Bayer and ARE.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Sectoral Asset Management is focused on global healthcare investment. | 2000 | sectoral.com | Montreal, Canada | |
Venture capital firm focused on life science companies | 1986 | archventure.com | Chicago, United States | |
PE firm investing in the US | nextechinvest.com | Zurich, Switzerland | ||
| vertexventureshc.com | ||||
PE firm investing in Asia | gthcap.com | Hong Kong, China | ||
Healthcare companies are invested in by this private equity firm. | pfmhealthsciences.com | San Francisco, United States | ||
Private equity fund focused on the biotechnology sector | logoscapital.com | San Francisco, United States | ||
Venture capital firm and foundation focused on biotech, cleantech, and media & entertainment, education, and more | cityhill.com | San Diego, United States | ||
Biotech startups are funded by this venture capital firm. | boxercap.com | San Diego, United States | ||
| cityhillventures.com |
Investor details for Boundless Bio
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Boundless Bio
43 people are tracked at Boundless Bio (13 in leadership, 12 in board & advisors, 18 in team); the tracked headcount is 64.
| Name | Role | Group |
|---|---|---|
Zachary Hornby | CEO, President, & Director | Leadership |
Jessica Oien | Chief Legal Officer, Corporate Secretary; Head Of Quality | Leadership |
Chris Hassig | Chief Scientific Officer | Leadership |
Amy Berkley | VP, Program Team Leadership & Strategic Alliances | Leadership |
Rebecca Reynolds | Director, Clinical Operations | Leadership |
James Lee | Sr. Director, Business Development | Leadership |
Adam Conde | Senior Director Information Technology | Leadership |
David Lu | Senior Director, Precision Medicine | Leadership |
David Williams | Director Of Accounting | Leadership |
Joan Chen | Executive Director, Bioinformatics | Leadership |
Deepti Wilkinson | Director, Drug Discovery And Translational Biology | Leadership |
Huikai Sun | Associate Director, Medicinal Chemistey | Leadership |
Ryan Hansen | Director | Leadership |
Kristina Burow | Director | Board & advisors |
Howard Chang | Scientific Advisor | Board & advisors |
Paul Mischel | Chairman of the Scientific Advisory Board | Board & advisors |
Jonathan Lim | Chairman & Co-Founder | Board & advisors |
Vineet Bafna | Scientific Advisor | Board & advisors |
Stephen Benkovic | Scientific Advisor | Board & advisors |
Christine Brennan | Director | Board & advisors |
23 more people are available in the full profile.
Complete people profiles for Boundless Bio
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Boundless Bio
Boundless Bio is a publicly listed company on the NASDAQ with ticker symbol BOLD in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date28 Mar 2024
- Listed onNASDAQ: BOLD
- Listed entityBoundless Bio, Inc.
- Exchange sectorHealth technology
- ISINUS10170A1007
- Share price$2.43 (-4.71% on the day) · 2026-10-13
- Market capitalisation$55.3M
- EPS (diluted, trailing year)$-2.86
- Volume (last session)463,158
Financials of Boundless Bio
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | -$58.2M | -$62.3M | |
| 2024 | -$65.4M | -$72.2M | |
| 2023 | -$49.4M | -$53.8M | |
| 2022 | -$45.9M | -$45.5M | |
| 2021 | -$25.2M | -$24.6M |
Detailed financial statements for Boundless Bio
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Boundless Bio
4 dated milestones of Boundless Bio across 6 years, from founding to its latest funding, stage changes and deals.
- Founded Boundless Bio is founded.
- Funding First funding round of $46.4M.
- Funding Latest funding round, Series C, of $100.0M.
- IPO Lists on the stock exchange (IPO).
Competitors of Boundless Bio
Boundless Bio has 3 listed competitors in our database, 3 of them funded. They include TScan Therapeutics, Lyell Immunopharma and GigaGen.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| tscan.com | 1995 | Boston, United States | $158.3M | 154 | T cell-based treatments for immunological and oncological disorders are developed. | |
| lyell.com | 2018 | San Francisco, United States | $493M | 224 | CAR-T and TIL immunotherapies for solid tumors are developed. | |
| gigagen.com | 2011 | San Francisco, United States | $36.13M | 36 | T-cell and antibody-based therapeutics are developed via single-cell sequencing platforms. |
Detailed competitors of Boundless Bio
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Boundless Bio
The website of Boundless Bio (boundlessbio.com) receives about 4.7K visits a month.
- Monthly visits4.7K
▼ 16.6% vs previous month
Top companies in Oncology
3 companies that operate in the same segment as Boundless Bio (Oncology) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Boundless Bio
Complete news archive for Boundless Bio
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Boundless Bio
Boundless Bio was founded in 2018 and raised its 1st funding round 1 year after it was founded.
Boundless Bio is headquartered in San Diego, United States. It is registered at San Diego, California, United States.
Boundless Bio is a funded company, having raised a total of $251.99M across 4 funding rounds to date. The company's 1st funding round was a Series A of $46.4M, raised on Sep 2019.
Boundless Bio has 64 employees.
Boundless Bio was founded in 2018 and is headquartered in San Diego, United States. Operations center on the biotechnology sector, where therapeutics are developed to address cancer through targeting extrachromosomal DNA (ecDNA). Emphasis is placed on ecDNA biology to create treatments for patients with oncogene-amplified cancers that are difficult to manage. The companys domain is boundlessbio.com.
Boundless Bio's top competitors include Lyell Immunopharma, GigaGen and TScan Therapeutics.
Boundless Bio offers ecDTx Therapies.
Yes, Boundless Bio is publicly traded on NASDAQ under the ticker symbol BOLD.
Boundless Bio has 21 investors. Key investors include Fidelity Investments, Bayer, ARE, Citadel, and RA Capital.
Boundless Bio operates through Boundless Bio, Inc..